Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients. (SPLENEVAC-2)

Evaluation of Immunological Response Following a Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients

This research is a multi-center French randomized and double blind phase IIb clinical trial evaluating 2 revaccination strategies against pneumococcal infections among splenectomised patients. The main objective is to evaluate at M13 the immunological response of 2 pneumococcal revaccination strategies (combined revaccination by a boost dose of PCV13 following 12 months later by PPS23, versus PPS23 alone) in splenectomised adults.

Study Overview

• Status: Active, not recruiting
• Conditions: Splenectomised Patients
• Intervention / Treatment: Biological: Prevenar13 (PCV13) and Pneumovax (PPS23); Biological: Blood sample; Biological: Placebo / Pneumovax (PPS23)

Detailed Description

For the prevention of invasive pneumococcal diseases, two polysaccharide vaccines are currently available: a non-conjugate vaccine, Pneumovax® (PPS23), and a conjugate vaccine, Prevenar13® (PCV13), inducing protection against 23 and 13 pneumococcal serotypes, respectively. The PPS23 is considered weakly immunogenic, especially in infants, elderly and immunocompromised patients, while PCV13 is now available for adults. In France, in April 2017, the new recommendations for at risk patients including asplenic patients are to revaccinate by PPS23 at least five years after the previous PPS23. However a phenomenon of vaccine hyporesponsiveness and a risk of immune tolerance to pneumococcus after repeated administrations of PPS23 are described. Large doses of polysaccharide antigens recruit memory and naive B cells, resulting in the production of low and high avidity antibodies, while low doses only stimulate memory B cells, inducing high affinity antibodies. Because of that, Swiss current recommendations are to revaccinate with PCV13 at 5 years the splenectomised patients. The recommendations of revaccination by PPS23 for USA or PCV13 for Switzerland have never been evaluated in clinical trial. Moreover, using combined PCV13/PPS23 could increase serotype coverage. Studying the immune response following combined revaccination by a boost dose of PCV13 following by PPS23 versus PPS23 alone will help to document and improve the vaccine recommendations.

The main objective is to evaluate at M13 the immunological response of 2 pneumococcal revaccination strategies (combined revaccination by a boost dose of PCV13 following 12 months later by PPS23, versus PPS23 alone), in splenectomised adults.

The primary endpoint is the proportion of patients responding to a minimum of 5 of the 9 serotypes analysed (9 serotypes among the 12 common serotypes to both PPS23 and PCV13: 1, 3, 6B, 7F, 9V, 14, 19A, 19F, and 23F) at M13 in each arm. A responder to a serotype is defined as a four-fold increase of the rate of OPA (OpsonoPhagocytic Assay) compared to baseline and titer ≥ LLOQ (Lower Limit of Quantification).

• Study Type: Interventional
• Enrollment (Actual): 39
• Phase: Phase 2

Contacts and Locations

Study Locations

• France
  • Paris, France, 75014
    • CIC 1417 Cochin-Pasteur - GH Broca-Cochin-Hôtel-Dieu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Age ≥ 18 years
2. Splenectomised patients.
3. For patients not enrolled in SPLENEVAC clinical trial: presence of Jolly Body at blood smear and spelenectomy confirmation by abdominal ultrasound.
4. Vaccinated according to the schedule of SPLENEVAC clinical trial (PCV13 / PPS23 two months later (until +4 months)), enrolled or not from this study. Vaccination of PPS23 must have been administered 5 years - 6 months/+ 1 year before inclusion.
5. Patients will be followed during the 24 months from the inclusion visit.
6. Patients must give written informed consent prior to any trial procedure.
7. Women of childbearing age must have an effective contraception during the first 13 months of the study.
8. Patients must be covered by social security regimen or equivalent.

Exclusion Criteria:

1. History of pneumococcal revaccination in the last five years.
2. Having received any another vaccines within 4 weeks prior to enrolment or who is planning to receive any vaccine (for example: ZOSTAVAX®) within the first 13 months of the study (excepted seasonal influenza vaccine which is permitted 4 weeks before and after each vaccination visit of the study and then allowed at any time during the study follow up. Furthermore, the vaccination against Sars-CoV-2 is allowed during the study with a minimum interval of 14 days between pneumococcal vaccine and Sars-Cov-2 vaccine injection)
3. History of known allergies to any component of both study vaccines (active substances, excipients or diphtheria toxoid).
4. History of anaphylactic reaction following vaccination.
5. Infusion of immunoglobulins within the three months preceding the inclusion.
6. Any pathology or condition that may impair the immune response, apart from splenectomy: immunosuppressive therapy in progress or in the 6 months prior to inclusion, hematopoietic stem cells allo / autograft, primary immunodeficiency, nephrotic syndrome, progressive neoplasia, evolutive cancer, cirrhosis, known infection to HIV and / or hepatitis B virus (HBV) (HBs Ag +) and / or hepatitis C virus (HCV), taking corticosteroids > 10mg for more than 14 days within the month preceding the inclusion , inhaled corticosteroid and cutaneous topical being allowed.
7. Coagulation disorder contra-indicating intramuscularly injections.
8. Acute respiratory tract infection or severe acute febrile illness or systemic reaction which could represent a significant risk in case of vaccination within the month before inclusion.
9. Pregnancy, breastfeeding or positive pregnancy test up to 13 months after inclusion.
10. History of suspected or documented invasive pneumococcal infection within the year before inclusion.
11. Immunosuppressive factors associated.
12. Enrolment in any other clinical trial during the whole trial period except observational study.
13. Adults under protection

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Prevenar13/ Pneumovax; Prime-boost strategy combining a single dose of 13-valent pneumococcal conjugate vaccine (Prevenar 13, PCV13) at month 0 (M0) followed by a single dose of 23-valent unconjugated vaccine (Pneumovax, PPS23) at month 12 (M12).	Biological: Prevenar13 (PCV13) and Pneumovax (PPS23); One dose of PCV13 at Month 0 and one dose of PPS23 at Month 12; Biological: Blood sample; an additional 5 mL sample of blood at one of the visits, preferably at the first visit, concerning patients included in Parisian centers who did not participate in SPLENEVAC 1 study.
Placebo Comparator: Placebo / Pneumovax; Standard strategy combining a single dose of placebo vaccine (Prevenar 13 placebo) at month 0 (M0) followed by a single dose of 23-valent unconjugated vaccine (Pneumovax, PPS23) at month 12 (M12)	Biological: Blood sample; an additional 5 mL sample of blood at one of the visits, preferably at the first visit, concerning patients included in Parisian centers who did not participate in SPLENEVAC 1 study.; Biological: Placebo / Pneumovax (PPS23); One dose of Placebo at Month 0 and one dose of PPS23 at Month 12

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Immunogenicity	Immune response at M13 against minimum of 5 of the 9 serotypes analysed (9 serotypes among the 12 common serotypes to both PPS23 and PCV13: 1, 3, 6B, 7F, 9V, 14, 19A, 19F, and 23F) in each arm. A responder to a serotype is defined as a four-fold increase of the rate of OpsonoPhagocytic Assay (OPA) compared to baseline (M0) and titer ≥ Lower Limit of Quantification (LLOQ).	at Month 13

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Enzyme-linked immunosorbent assay (ELISA) antibody dosages	ELISA antibody concentration against 9 common serotypes (1, 3, 6B, 7F, 9V, 14, 19A, 19F and 23F), and, the proportion of positive serotypes: serotype is considered positive if the immunoglobulin G (IgG) antibody concentration in ELISA shows a two-fold increase from baseline (M0) in each arm from baseline.	Month 0 to Month 24
Enzyme-linked immunosorbent assay (ELISA) antibody dosages	ELISA antibody concentration against 9 common serotypes (1, 3, 6B, 7F, 9V, 14, 19A, 19F and 23F), and, the proportion of positive serotypes: serotype is considered positive if the IgG antibody concentration is ≥ 1μg/ml in each arm from baseline.	Month 0 to Month 24
Enzyme-linked immunosorbent assay (ELISA) antibody dosages	ELISA antibody concentration against 9 common serotypes (1, 3, 6B, 7F, 9V, 14, 19A, 19F and 23F), and, the proportion of positive serotypes: serotype is considered positive if the IgG antibody concentration shows a two-fold increase from baseline (M0) in each arm and IgG ≥ 1μg/ml from baseline.	Month 0 to Month 24
Titration of OPA -	OPA titers against 9 common serotypes (1, 3, 6B, 7F, 9V, 14, 19A, 19F and 23F) and the proportion of positive serotype: serotype is considered positive if the antibody titer shows a four-fold increase from baseline (M0).	at Month 0, Month 13 and Month 24
Titration of OPA -	OPA titers against 9 common serotypes (1, 3, 6B, 7F, 9V, 14, 19A, 19F and 23F) and the proportion of positive serotype: serotype is considered positive if the antibody titer ≥ LLOQ.	at Month 0, Month 13 and Month 24
Titration of OPA -	OPA titers against 9 common serotypes (1, 3, 6B, 7F, 9V, 14, 19A, 19F and 23F) and the proportion of positive serotype: serotype is considered positive if the antibody titer shows a four-fold increase from baseline (M0) and titer ≥ LLOQ.	at Month 0, Month 13 and Month 24
ELISA antibody dosages	ELISA antibody concentration against 3 uncommon specific serotypes of PPS23 (12F, 10A and15B) and the proportion of positive serotypes: serotype is considered positive if the IgG antibody concentration shows a two-fold increase from baseline (M12) in each arm and IgG ≥ 1 μg/ml	at Month 12, Month 13 and Month 24
ELISA antibody dosages	ELISA antibody concentration against 3 uncommon specific serotypes of PPS23 (12F, 10A and 15B) and the proportion of positive serotypes: serotype is considered positive if the IgG antibody concentration shows a two-fold increase from baseline (M12) in each arm.	at Month 12, Month 13 and Month 24
ELISA antibody dosages	ELISA antibody concentration against 3 uncommon specific serotypes of PPS23 (12F, 10A and 15B) and the proportion of positive serotypes: serotype is considered positive if the IgG antibody concentration in ELISA is ≥ 1μg/ml in each arm.	at Month 12, Month 13 and Month 24
Sustainability and evolution of the immune response	Measure of ELISA concentration and OPA titers for the 9 PCV13 serotypes in each arm.	at Month 0 and Month 24
ELISA antibody dosages	ELISA antibody concentration against 9 common specific serotypes (1, 3, 6B, 7F, 9V, 14, 19A, 19F and 23F) and the proportion of positive serotype: serotype is considered positive if the IgG antibody concentration in ELISA and shows a two-fold increase from baseline (M0) in each arm in SPLENEVAC 1	at Month 3
Percentage of patients presenting local or systemic reactions post-immunization	Number of subjects with local and systemic reactions following vaccinations (tolerability) in each arm.	Month0 to Month 24

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris
• Collaborators: Recherche Clinique Paris Descartes Necker Cochin Sainte Anne; EUCLID Clinical Trial Platform; CIC 1417 Cochin-Pasteur; I-REIVAC Innovative Clinical Research Network In Vaccinology
• Investigators: Principal Investigator: Odile Launay, MD,PhD, CIC 1417 Clinical Center Investigation - Cochin Hospital, AP-HP; Principal Investigator: Olivier Lortholary, Md,PhD, Service des Maladies Infectieuses et Tropicales, Necker-Enfants malades Hospital, AP-HP; Principal Investigator: Hélène Coignard-Biehler, MD,PhD, COREB - Hospices Civils de Lyon; Principal Investigator: Marc Michel, MD,PhD, Service de médecine interne, Henri Mondor Hospital, APHP; Principal Investigator: Benjamin Rossi, MD, Service de Médecine interne et de Maladies infectieuses, Robert Ballanger Hospital

Study record dates

Study Major Dates

• Study Start (Actual): August 27, 2019
• Primary Completion (Anticipated): June 1, 2023
• Study Completion (Anticipated): June 1, 2024

Study Registration Dates

• First Submitted: February 12, 2019
• First Submitted That Met QC Criteria: March 12, 2019
• First Posted (Actual): March 13, 2019

Study Record Updates

• Last Update Posted (Actual): October 12, 2022
• Last Update Submitted That Met QC Criteria: October 10, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Keywords: Pneumovax; Splenectomy; Vaccination / Re-vaccination; Asplenic patient; Pneumococcal infections; immunological response; Prevenar13
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Immunologic Factors; Heptavalent Pneumococcal Conjugate Vaccine
• Other Study ID Numbers: P170934J; 2018-003068-29 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No